Your browser doesn't support javascript.
loading
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).
Tovey, Holly; Sipos, Orsolya; Parker, Joel S; Hoadley, Katherine A; Quist, Jelmar; Kernaghan, Sarah; Kilburn, Lucy; Salgado, Roberto; Loi, Sherene; Kennedy, Richard D; Roxanis, Ioannis; Gazinska, Patrycja; Pinder, Sarah E; Bliss, Judith; Perou, Charles M; Haider, Syed; Grigoriadis, Anita; Tutt, Andrew; Cheang, Maggie Chon U.
Afiliação
  • Tovey H; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Sipos O; Breast Cancer Now Toby Robinsons Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Parker JS; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Hoadley KA; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Quist J; The Breast Cancer Now Unit, King's College London Faculty of Life Sciences and Medicine, London, United Kingdom.
  • Kernaghan S; School of Cancer and Pharmaceutical Sciences, King's College London Faculty of Life Sciences and Medicine, London, United Kingdom.
  • Kilburn L; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Salgado R; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Loi S; Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium.
  • Kennedy RD; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
  • Roxanis I; ALMAC Diagnostic Services, Northern Ireland, United Kingdom.
  • Gazinska P; Breast Cancer Now Toby Robinsons Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Pinder SE; Breast Cancer Now Toby Robinsons Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Bliss J; Biobank Research Group, Lukasiewicz Research Network - PORT Polish Center for Technology Development, Wroclaw, Poland.
  • Perou CM; School of Cancer and Pharmaceutical Sciences, King's College London Faculty of Life Sciences and Medicine, London, United Kingdom.
  • Haider S; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Grigoriadis A; Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Tutt A; Breast Cancer Now Toby Robinsons Research Centre, The Institute of Cancer Research, London, United Kingdom.
  • Cheang MCU; The Breast Cancer Now Unit, King's College London Faculty of Life Sciences and Medicine, London, United Kingdom.
Clin Cancer Res ; 29(18): 3691-3705, 2023 09 15.
Article em En | MEDLINE | ID: mdl-37574209
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Neoplasias de Mama Triplo Negativas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido